# A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

> **NCT01441388** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Carcinoma, Renal Cell
- Glioblastoma
- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Crizotinib plus VEGF inhibitor combinations
- **DRUG:** Crizotinib plus axitinib
- **DRUG:** Crizotinib plus sunitinib
- **DRUG:** Crizotinib plus axitinib
- **DRUG:** Crizotinib plus sunitinib
- **DRUG:** Crizotinib plus bevacizumab
- **DRUG:** Crizotinib plus sorafenib

## Key facts

- **NCT ID:** NCT01441388
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business/Operational issues
- **Last updated:** 2011-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441388, "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01441388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*